Roche scores adjuvant lung cancer approval for TecentriqRoche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), Share XRoche scores adjuvant lung cancer approval for Tecentriqhttps://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/
FDA panel backs booster shot for J&J COVID-19 vaccineAn FDA advisory committee voted unanimously in favour of a booster dose of Johnson & Johnson’s one-shot COVID-19 Share XFDA panel backs booster shot for J&J COVID-19 vaccinehttps://pharmaphorum.com/news/fda-panel-backs-booster-shot-for-jj-covid-19-vaccine/
UK hospital will use MindMaze game to aid stroke recoveryA hospital trust has become the first in the UK to deploy a gaming system developed by Swiss Share XUK hospital will use MindMaze game to aid stroke recoveryhttps://pharmaphorum.com/news/uk-hospital-will-use-mindmaze-game-to-aid-stroke-recovery/
Califf re-joining FDA would be positive for industry; analystWith rumours growing that that ex-FDA head Robert Califf looks set to receive President Joe Biden’s nomination to Share XCaliff re-joining FDA would be positive for industry; analysthttps://pharmaphorum.com/news/califf-re-joining-fda-would-be-positive-for-industry-analyst/
Healthware Group appoints Eugene Borukhovich as senior advisorDigital Health veteran Eugene Borukhovich has joined Healthware Group as senior advisor to its Media and Community business Share XHealthware Group appoints Eugene Borukhovich as senior advisorhttps://pharmaphorum.com/news/healthware-group-appoints-eugene-borukhovich-senior-advisor/
WHO plans pandemic prevention study of COVID’s originsThe World Health Organization has set up a new scientific group to study the origins of COVID-19 in Share XWHO plans pandemic prevention study of COVID’s originshttps://pharmaphorum.com/news/who-pandemic-prevention-study-covids-origins/
Headspace and Ginger finalise $3bn digital mental health mergerHeadspace and Ginger have completed their $3 billion combination to create Headspace Health, a new frontrunner in the Share XHeadspace and Ginger finalise $3bn digital mental health mergerhttps://pharmaphorum.com/news/headspace-and-ginger-finalise-3bn-digital-mental-health-merger/
Digital therapeutics world first for Big Health in ScotlandUK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety Share XDigital therapeutics world first for Big Health in Scotlandhttps://pharmaphorum.com/news/digital-therapeutics-world-first-big-health-scotland/
Positive safety data for long-term use of MS drug KesimptaMultiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended Share XPositive safety data for long-term use of MS drug Kesimptahttps://pharmaphorum.com/news/positive-safety-data-long-term-ms-drug-kesimpta/
Keytruda approved as first-line advanced cervical cancer therapyThe FDA has approved Merck’s Keytruda as a first-line therapy for advanced cervical cancer. Keytruda (pembrolizumab) can be Share XKeytruda approved as first-line advanced cervical cancer therapyhttps://pharmaphorum.com/news/keytruda-approved-first-line-advanced-cervical-cancer-therapy/
Spark to use CombiGene therapy to target focal epilepsySpark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal Share XSpark to use CombiGene therapy to target focal epilepsyhttps://pharmaphorum.com/news/spark-combigene-therapy-target-focal-epilepsy/
Actemra shortage spills over to include Sanofi’s rival KevzaraRoche’s Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to Share XActemra shortage spills over to include Sanofi’s rival Kevzarahttps://pharmaphorum.com/news/actemra-shortage-spills-over-to-include-sanofis-rival-kevzara/
J&J’s long-serving R&D chief Paul Stoffels announces retirementPaul Stoffels is bringing a nine-year tenure as head of R&D at Johnson & Johnson to a close, Share XJ&J’s long-serving R&D chief Paul Stoffels announces retirementhttps://pharmaphorum.com/news/jjs-long-serving-rd-chief-paul-stoffels-announces-retirement/
Alnylam launches digital tool for ATTR amyloidosis patientsAlnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to Share XAlnylam launches digital tool for ATTR amyloidosis patientshttps://pharmaphorum.com/news/alnylam-launches-digital-tool-for-aatr-amyloidosis-patients/
Merck files pill for milder COVID, as AZ showcases its antibody dataAs expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral Share XMerck files pill for milder COVID, as AZ showcases its antibody datahttps://pharmaphorum.com/news/merck-files-pill-for-milder-covid-as-az-showcases-its-antibody-data/
Data dive finds cheap diuretic could be Alzheimer’s drugA data-mining study conducted by researchers in the US has found that an already-approved diuretic drug could have Share XData dive finds cheap diuretic could be Alzheimer’s drughttps://pharmaphorum.com/news/data-dive-finds-cheap-diuretic-could-be-alzheimers-drug/
Supernus bulks up its Parkinson’s portfolio with Adamas takeoverSupernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Share XSupernus bulks up its Parkinson’s portfolio with Adamas takeoverhttps://pharmaphorum.com/news/supernus-bulks-up-its-parkinsons-portfolio-with-adamas-takeover/
Scotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewPatients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb’s immunotherapy Opdivo Share XScotland backs Cabometyx combo for kidney cancer, amid stalled NICE reviewhttps://pharmaphorum.com/news/scotland-backs-cabometyx-combo-for-kidney-cancer-amid-stalled-nice-review/
Future focus: 3 tools for launching fast in the face of uncertainty Share XFuture focus: 3 tools for launching fast in the face of uncertaintyhttps://pharmaphorum.com/partner-content/future-focus-3-tools-for-launching-fast-in-the-face-of-uncertainty/
Are You Speaking a Patient’s Language?: 5 Terms Used By Patients Share XAre You Speaking a Patient’s Language?: 5 Terms Used By Patientshttps://pharmaphorum.com/partner-content/are-you-speaking-a-patients-language-5-terms-used-by-patients/
Identifying And Engaging Digital Opinion Leaders Share XIdentifying And Engaging Digital Opinion Leadershttps://pharmaphorum.com/partner-content/identifying-and-engaging-digital-opinion-leaders/
Release of International Book: DTx: An Opportunity for Italy and Beyond Share XRelease of International Book: DTx: An Opportunity for Italy and Beyondhttps://pharmaphorum.com/partner-content/release-of-international-book-dtx-an-opportunity-for-italy-and-beyond/
AXON appoints Colette Balaam as its new US Managing Partner Share XAXON appoints Colette Balaam as its new US Managing Partnerhttps://pharmaphorum.com/partner-content/axon-appoints-colette-balaam-as-its-new-us-managing-partner/
Prescient Healthcare Group to Partner with Bridgepoint Development Capital Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
